Table 3 A summary of randomized controlled trials of the use of misoprostol ripening of the cervix before hysteroscopy
Reference | Misoprostol | Spontaneous dilator (mean±SD, mm) | Comparison group | Spontaneous dilator (mean±SD, mm) |
|---|---|---|---|---|
[10] | 200 μg, 9–10 h, vaginally, n=46 | 7.0±1.0 | Placebo n=45 | 3.8±1.2 |
[11] | 200 μg, 9–10 h, vaginally, n=73 | 7.3±0.7 | Placebo n=79 | 3.8±1.1 |
[15]a | 200 μg, 8 h, vaginally, n=72 | 7.5±1.2 | Laminaria 8 h, n=72 | 7.6±1.2 |
[12] | 400 μg, 12 h, vaginally, n=51 | 7.6±1.4 | No agent n=54 | 5.0±1.1 |
Current study | 400 μg, 12 h, vaginally, n=53 | 8.0±1.8 | The synthetic osmotic dilator 12 h, n=47 | 9.6±2.2 |